Experienced in Malignant Mixed Mullerian Tumor

Dr. Devansu Tewari

Oncology | Obstetrics and Gynecology
Kaiser Permanente
Alton/sand Canyon Medical Offices
6650 Alton Pkwy, 
Irvine, CA 
Accepting New Patients
Experienced in Malignant Mixed Mullerian Tumor
Kaiser Permanente
Alton/sand Canyon Medical Offices
6650 Alton Pkwy, 
Irvine, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Devansu Tewari is an Oncologist and an Obstetrics and Gynecologist in Irvine, California. Dr. Tewari is rated as an Experienced provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Human Papillomavirus Infection, Ovarian Cancer, Vaginal Cancer, and Cervical Cancer. Dr. Tewari is currently accepting new patients.

His clinical research consists of co-authoring 16 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in OR
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Alton/sand Canyon Medical Offices
6650 Alton Pkwy, Irvine, CA 92618

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Other, Biological
Study Drug: Vigil
Study Phase: Phase 2
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)
Enrollment Status: Completed
Publish Date: April 05, 2023
Intervention Type: Drug, Biological
Study Drugs: Vigil Tumor Cells, Atezolizumab
Study Phase: Phase 2
View 2 Less Clinical Trials

16 Total Publications

Locally-tailored vs. centrally-administered strategies for implementation of primary human papillomavirus (HPV) screening in an integrated healthcare system: a qualitative research study.
Locally-tailored vs. centrally-administered strategies for implementation of primary human papillomavirus (HPV) screening in an integrated healthcare system: a qualitative research study.
Journal: Frontiers in health services
Published: March 18, 2025
Similar Doctors
Distinguished in Malignant Mixed Mullerian Tumor
Dr. John V. Brown
Oncology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. John V. Brown
Oncology
16105 Sand Canyon Avenue, Suite 260, 
Irvine, CA 
 (2.5 miles away)
949-642-1361
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Brown is an Oncologist in Irvine, California. Dr. Brown is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Ovarian Carcinosarcoma, Endometrial Cancer, Sertoli-Leydig Cell Tumor, and Malignant Mixed Mullerian Tumor. Dr. Brown is currently accepting new patients.

Distinguished in Malignant Mixed Mullerian Tumor
Dr. Krishnansu S. Tewari
Oncology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Krishnansu S. Tewari
Oncology
1000 West La Veta Avenue, Floor 1, 
Orange, CA 
 (9.9 miles away)
714-734-6225
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Krishnansu Tewari is an Oncologist in Orange, California. Dr. Tewari is rated as an Elite provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Cervical Cancer, Ovarian Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Lymphadenectomy. Dr. Tewari is currently accepting new patients.

Distinguished in Malignant Mixed Mullerian Tumor
Dr. Joshua G. Cohen
Oncology
Distinguished in Malignant Mixed Mullerian Tumor
Dr. Joshua G. Cohen
Oncology
2151 North Harbor Boulevard, Suite 3100, 
Anchorage, CA 
 (18.7 miles away)
714-446-5830
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joshua Cohen is an Oncologist in Anchorage, California. Dr. Cohen is rated as a Distinguished provider by MediFind in the treatment of Malignant Mixed Mullerian Tumor. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Malignant Mixed Mullerian Tumor, Hernia Surgery, and Lymphadenectomy. Dr. Cohen is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tewari's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile